The critical role of AR as a regulator of DDR genes has been previously reported, leading to the combination of DDR inhibitors and AR deprivation therapy as a new treatment strategy for aggressive prostate cancer (Karanika et al., 2015; Rao et al., 2022; Unlu and Kim 2022). The gene discussed is AR; the disease is prostate carcinoma.